CD274 and non-small cell squamous lung carcinoma: There are few recommendations for the replacement of different immune checkpoint inhibitors in domestic and international reports.<h4>Case presentation</h4>We report a case of a patient with squamous non-small cell lung carcinoma (squamous NSCLC) who developed cardiotoxicity after being treated with a programmed death-1 (PD-1) inhibitor and then changed to a PD-L1 inhibitor to continue the treatment.